Cargando…

Galectin-3 and Epithelial MUC1 Mucin—Interactions Supporting Cancer Development

SIMPLE SUMMARY: MUC1 mucin with T antigen and galectin-3 with high affinity to T disaccharide are both overexpressed in a variety of human cancers. Their mutual interactions support cancer development, attenuate anoikis, promote cancer cells proliferation, invasiveness and metastasis. The inhibition...

Descripción completa

Detalles Bibliográficos
Autor principal: Radziejewska, Iwona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216753/
https://www.ncbi.nlm.nih.gov/pubmed/37345016
http://dx.doi.org/10.3390/cancers15102680
_version_ 1785048373700591616
author Radziejewska, Iwona
author_facet Radziejewska, Iwona
author_sort Radziejewska, Iwona
collection PubMed
description SIMPLE SUMMARY: MUC1 mucin with T antigen and galectin-3 with high affinity to T disaccharide are both overexpressed in a variety of human cancers. Their mutual interactions support cancer development, attenuate anoikis, promote cancer cells proliferation, invasiveness and metastasis. The inhibition of MUC1/T antigen—galectin-3 interactions may be a potential strategy to reduce tumor progression and metastasis. The aim of this review is to summarize the current knowledge about the relationship between MUC1 and galectin-3. ABSTRACT: Aberrant glycosylation of cell surface proteins is a very common feature of many cancers. One of the glycoproteins, which undergoes specific alterations in the glycosylation of tumor cells is epithelial MUC1 mucin, which is highly overexpressed in the malignant state. Such changes lead to the appearance of tumor associated carbohydrate antigens (TACAs) on MUC1, which are rarely seen in healthy cells. One of these structures is the Thomsen-Friedenreich disaccharide Galβ1-3GalNAc (T or TF antigen), which is typical for about 90% of cancers. It was revealed that increased expression of the T antigen has a big impact on promoting cancer progression and metastasis, among others, due to the interaction of this antigen with the β-galactose binding protein galectin-3 (Gal-3). In this review, we summarize current information about the interactions between the T antigen on MUC1 mucin and Gal-3, and their impact on cancer progression and metastasis.
format Online
Article
Text
id pubmed-10216753
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102167532023-05-27 Galectin-3 and Epithelial MUC1 Mucin—Interactions Supporting Cancer Development Radziejewska, Iwona Cancers (Basel) Review SIMPLE SUMMARY: MUC1 mucin with T antigen and galectin-3 with high affinity to T disaccharide are both overexpressed in a variety of human cancers. Their mutual interactions support cancer development, attenuate anoikis, promote cancer cells proliferation, invasiveness and metastasis. The inhibition of MUC1/T antigen—galectin-3 interactions may be a potential strategy to reduce tumor progression and metastasis. The aim of this review is to summarize the current knowledge about the relationship between MUC1 and galectin-3. ABSTRACT: Aberrant glycosylation of cell surface proteins is a very common feature of many cancers. One of the glycoproteins, which undergoes specific alterations in the glycosylation of tumor cells is epithelial MUC1 mucin, which is highly overexpressed in the malignant state. Such changes lead to the appearance of tumor associated carbohydrate antigens (TACAs) on MUC1, which are rarely seen in healthy cells. One of these structures is the Thomsen-Friedenreich disaccharide Galβ1-3GalNAc (T or TF antigen), which is typical for about 90% of cancers. It was revealed that increased expression of the T antigen has a big impact on promoting cancer progression and metastasis, among others, due to the interaction of this antigen with the β-galactose binding protein galectin-3 (Gal-3). In this review, we summarize current information about the interactions between the T antigen on MUC1 mucin and Gal-3, and their impact on cancer progression and metastasis. MDPI 2023-05-09 /pmc/articles/PMC10216753/ /pubmed/37345016 http://dx.doi.org/10.3390/cancers15102680 Text en © 2023 by the author. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Radziejewska, Iwona
Galectin-3 and Epithelial MUC1 Mucin—Interactions Supporting Cancer Development
title Galectin-3 and Epithelial MUC1 Mucin—Interactions Supporting Cancer Development
title_full Galectin-3 and Epithelial MUC1 Mucin—Interactions Supporting Cancer Development
title_fullStr Galectin-3 and Epithelial MUC1 Mucin—Interactions Supporting Cancer Development
title_full_unstemmed Galectin-3 and Epithelial MUC1 Mucin—Interactions Supporting Cancer Development
title_short Galectin-3 and Epithelial MUC1 Mucin—Interactions Supporting Cancer Development
title_sort galectin-3 and epithelial muc1 mucin—interactions supporting cancer development
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216753/
https://www.ncbi.nlm.nih.gov/pubmed/37345016
http://dx.doi.org/10.3390/cancers15102680
work_keys_str_mv AT radziejewskaiwona galectin3andepithelialmuc1mucininteractionssupportingcancerdevelopment